The Schulte Institute

The Schulte Institute in Scottsdale, Arizona offers Spravato (esketamine), an FDA-approved nasal spray for adults with treatment-resistant depression and for major depressive disorder with acute suicidal thoughts. Dr. Henry Schulte provides personalized treatment in a safe, supervised clinical setting through the Spravato REMS program.

Unlike traditional antidepressants that work on serotonin or dopamine pathways, Spravato targets the NMDA receptor, which is involved in synaptic plasticity and mood regulation. This mechanism can produce rapid antidepressant effects, often within hours to days. Patients self-administer the spray under direct supervision and remain in the office for at least two hours of monitoring, with a designated driver required.

Treatment is structured in phases, beginning with twice-weekly induction dosing and gradually reducing in frequency based on response. The Schulte Institute also offers NeuroStar Advanced TMS therapy for depression, OCD, and off-label conditions.